310 related articles for article (PubMed ID: 27856443)
1. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.
Eckert MA; Pan S; Hernandez KM; Loth RM; Andrade J; Volchenboum SL; Faber P; Montag A; Lastra R; Peter ME; Yamada SD; Lengyel E
Cancer Discov; 2016 Dec; 6(12):1342-1351. PubMed ID: 27856443
[TBL] [Abstract][Full Text] [Related]
2. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.
Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL
J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554
[TBL] [Abstract][Full Text] [Related]
3. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
6. Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer.
Byun JM; Cho HJ; Lee DS; Yoon HK; Kim YN; Im DH; Kim DH; Lee KB; Sung MS; Jeong DH
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):107-111. PubMed ID: 36720520
[TBL] [Abstract][Full Text] [Related]
7. High grade serous ovarian carcinomas originate in the fallopian tube.
Labidi-Galy SI; Papp E; Hallberg D; Niknafs N; Adleff V; Noe M; Bhattacharya R; Novak M; Jones S; Phallen J; Hruban CA; Hirsch MS; Lin DI; Schwartz L; Maire CL; Tille JC; Bowden M; Ayhan A; Wood LD; Scharpf RB; Kurman R; Wang TL; Shih IM; Karchin R; Drapkin R; Velculescu VE
Nat Commun; 2017 Oct; 8(1):1093. PubMed ID: 29061967
[TBL] [Abstract][Full Text] [Related]
8. Two different, mutually exclusively distributed,
Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689
[TBL] [Abstract][Full Text] [Related]
9. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
Toptas T; Pestereli E; Simsek T; Bozkurt S; Erdogan G; Karaveli S
J Cancer Res Ther; 2018; 14(3):587-592. PubMed ID: 29893323
[TBL] [Abstract][Full Text] [Related]
11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
12. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
Mahe E; Tang S; Deb P; Sur M; Lytwyn A; Daya D
Int J Gynecol Pathol; 2013 Jul; 32(4):353-7. PubMed ID: 23722507
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.
Ducie J; Dao F; Considine M; Olvera N; Shaw PA; Kurman RJ; Shih IM; Soslow RA; Cope L; Levine DA
Nat Commun; 2017 Oct; 8(1):990. PubMed ID: 29042553
[TBL] [Abstract][Full Text] [Related]
14. Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
[TBL] [Abstract][Full Text] [Related]
15. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
17. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
Auer K; Bachmayr-Heyda A; Aust S; Grunt TW; Pils D
Cancer Lett; 2017 Mar; 388():158-166. PubMed ID: 27940126
[TBL] [Abstract][Full Text] [Related]
18. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.
Brown Y; Hua S; Tanwar PS
Matrix Biol; 2023 Apr; 118():16-46. PubMed ID: 36781087
[TBL] [Abstract][Full Text] [Related]
19. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
20. DNA Methylation Profiling of Premalignant Lesions as a Path to Ovarian Cancer Early Detection.
Ishak CA; De Carvalho DD
Clin Cancer Res; 2020 Dec; 26(23):6083-6085. PubMed ID: 32988966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]